Edition:
United States

Obalon Therapeutics Inc (OBLN.OQ)

OBLN.OQ on NASDAQ Stock Exchange Global Market

3.47USD
12:32pm EDT
Change (% chg)

$0.02 (+0.58%)
Prev Close
$3.45
Open
$3.46
Day's High
$3.55
Day's Low
$3.46
Volume
2,243
Avg. Vol
57,784
52-wk High
$13.18
52-wk Low
$3.25

Latest Key Developments (Source: Significant Developments)

Obalon Therapeutics Q4 Loss Per Share $0.60
Monday, 5 Mar 2018 03:01pm EST 

March 5 (Reuters) - Obalon Therapeutics Inc ::OBALON ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $3.7 MILLION VERSUS $800,000.Q4 LOSS PER SHARE $0.60.  Full Article

Obalon Announces Termination Of Public Offering Of Common Stock
Tuesday, 23 Jan 2018 09:13am EST 

Jan 23 (Reuters) - Obalon Therapeutics Inc ::OBALON ANNOUNCES TERMINATION OF PUBLIC OFFERING OF COMMON STOCK.OBALON THERAPEUTICS- TERMINATION OF UNDERWRITING AGREEMENT,CANCELLATION OF PREVIOUSLY ANNOUNCED OFFERING OF 5.5 MILLION SHARES AT PRICE OF $5.50/SHARE.OBALON - PURPORTED WHISTLEBLOWER CONTACTED CO'S INDEPENDENT AUDITORS TO ALLEGE "IMPROPER REVENUE RECOGNITION" IN FISCAL Q4.OBALON - ALLEGATIONS BY PURPORTED WHISTLEBLOWER WERE REPORTED TO CO LATE ON JAN. 22.OBALON -‍CO'S AUDIT COMMITTEE TO OVERSEE AN INTERNAL INVESTIGATION OF ALLEGATIONS RELATING TO ALLEGEDLY "IMPROPER REVENUE RECOGNITION" DURING Q4 2017.OBALON - REPORTING ALLEGATIONS TO CO ON JAN. 22 MADE IT "INFEASIBLE" TO COMPLETE INVESTIGATION BEFORE INTENDED CLOSING OF PUBLIC OFFERING.OBALON - DOESN'T CURRENTLY BELIEVE MATERIAL ADJUSTMENTS TO PRELIM, UNAUDITED REVENUE FOR Q4 2017, FY2017 REPORTED WILL BE REQUIRED DUE TO ALLEGATIONS.  Full Article

Obalon Therapeutics prices offering of 5.5 mln shares at $5.50 per share
Thursday, 18 Jan 2018 10:00pm EST 

Jan 18 (Reuters) - Obalon Therapeutics Inc ::OBALON THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.OBALON THERAPEUTICS INC - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF COMMON STOCK AT A OFFERING PRICE OF $5.50 PER SHARE​.  Full Article

Obalon Therapeutics Announces Proposed Public Offering Of $35 Mln Shares
Tuesday, 16 Jan 2018 04:01pm EST 

Jan 16 (Reuters) - Obalon Therapeutics Inc ::OBALON THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.OBALON THERAPEUTICS INC - ‍COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF $35 MILLION OF SHARES OF ITS COMMON STOCK​.  Full Article

Obalon Therapeutics Q3 loss per share $0.55
Friday, 3 Nov 2017 07:29am EDT 

Nov 3 (Reuters) - Obalon Therapeutics Inc :Obalon announces third quarter 2017 financial results.Q3 revenue $2.8 million versus I/B/E/S view $2.9 million.Q3 loss per share $0.55.Q3 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S.  Full Article

Obalon Therapeutics & Sono Bello announce agreement to offer novel weight loss treatment
Thursday, 2 Nov 2017 04:06pm EDT 

Nov 2 (Reuters) - Obalon Therapeutics Inc :Obalon Therapeutics Inc and Sono Bello announce agreement to offer novel weight loss treatment in Sono Bello centers.Obalon Therapeutics Inc - ‍co, Sono Bello announced that they had reached an agreement to begin offering Obalon balloon system​.Obalon Therapeutics Inc - ‍Obalon balloon system will be exclusive non-invasive weight loss technology offered in Sono Bello centers​.  Full Article

Obalon Therapeutics files for mixed shelf of up to $100 mln
Wednesday, 1 Nov 2017 07:39pm EDT 

Nov 1 (Reuters) - Obalon Therapeutics Inc ::Files for mixed shelf of up to $100 million - SEC filing‍​.Says in addition, selling stockholder may offer and sell up to 150,000 shares of co's common stock.  Full Article

Obalon Q2 loss per share $0.46
Wednesday, 2 Aug 2017 07:59am EDT 

Aug 2 (Reuters) - Obalon Therapeutics Inc :Obalon announces second quarter 2017 financial results.Q2 revenue $2.0 million versus i/b/e/s view $1.7 million.Q2 loss per share $0.46.Q2 earnings per share view $-0.44 -- Thomson Reuters I/B/E/S.Obalon therapeutics inc - ‍at june 30, 2017, cash, cash equivalents and short-term investments were $60.7 million and long-term debt was $10.0 million.​.  Full Article

Obalon receives regulatory approvals to commercialize in select Middle East markets
Thursday, 11 May 2017 08:02am EDT 

May 11 (Reuters) - Obalon Therapeutics Inc :Obalon receives regulatory approvals to commercialize in select middle east markets.Obalon therapeutics inc - intends to fulfill an initial order to its middle east distributor, bader sultan, during q2 of 2017.  Full Article

Obalon Q1 loss per share $0.47
Wednesday, 10 May 2017 08:01am EDT 

May 10 (Reuters) - Obalon Therapeutics Inc :Obalon announces first quarter 2017 financial results.Q1 revenue $1.5 million versus i/b/e/s view $1.3 million.Q1 loss per share $0.47.Q1 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Obalon Therapeutics Q4 Loss Per Share $0.60

* OBALON ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS